In. Play from Briefing. Stock indices extend below narrow midday ranges - - Dow - 3. S& P - 3. 6, Nasdaq Comp - 7. SPY) : The S& P is back near a short term support at 1. Clearwire: Special Committee and Board of Directors change recommendation in favor of Sprint (S) merger based on revised offer of $5. CLWR) : Co announced that its board of directors, based on the unanimous recommendation of the Special Committee consisting of independent, non- Sprint- affiliated directors, recommended that stockholders accept a revised offer from Sprint (S) to acquire the approximately 5. Company it does not currently own for $5. Clearwire at more than $1. MHZ pop. As such, the board of directors present unanimously recommended that stockholders vote FOR the proposed transaction with Sprint and all other proposals set forth in the proxy statement, and not tender any shares of Class A common stock pursuant to the DISH Network (DISH) tender offer. Pharmacyclics: Ibrutinib monotherapy clinical trial data in patients with Waldenstrom's Macroglobulinemia presented at the International Conference on Malignant Lymphoma (PCYC) : Co announced results of a study evaluating ibrutinib, an investigational oral Bruton's tyrosine kinase (: BTK) inhibitor in patients with Waldenstrom's Macroglobulinemia (WM). ★ Solar Battery Charger Sizing - Signs Your Car Battery Is Dead Buy Used Batteries Dallas Benefit Of Recycling Batteries. ★ Hood Mounted Vehicle Solar Battery Charger - How Long Do I Charge A Dead Car Battery How To Use 2 Bank On Board Battery Charger How To Test Batteries With A Voltmeter. Windows startup programs - Database search. If you're frustrated with the time it takes your Windows 10/8/7/Vista/XP PC to boot and then it seems to be running slowly. View and Download CNC Fanuc 16i-lb maintenance manual online. Fanuc 16i-lb Controller pdf manual download. Pharmacyclics is jointly developing ibrutinib with Janssen Research & Development, LLC. The data were presented today at the International Conference on Malignant Lymphoma (: ICML), taking place in Lugano, Switzerland. Thirty five relapsed/refractory WM patients who received a median of 2 prior therapies were evaluated. Key findings presented at ICML include: 2: 1. Bristol- Myers: FDA approves U. S. product labeling update for Sprycel (dasatinib) to include three- year first- line and five- year second- line efficacy and safety data in chronic myeloid leukemia in chronic phase (BMY) : Co and Otsuka America Pharmaceutical announced that the FDA has approved an update to the Sprycel (dasatinib) product labeling. The labeling now includes three- year efficacy and safety data in patients with newly diagnosed Philadelphia chromosome- positive (Ph+) chronic myeloid leukemia (: CML) in chronic phase (CP) and five- year data in CP Ph+ CML patients who are resistant or intolerant to Gleevec. The effectiveness of Sprycel is based on cytogenetic response and major molecular response rates. The trial is ongoing and further data will be required to determine long- term outcome. Information added to the Sprycel label in the first- line CP Ph+ CML setting is based on three- year data from DASISION (Dasatinib versus Imatinib Study in Treatment- Naive CML Patients), an open- label, randomized, Phase 3 international trial. In the study, Sprycel demonstrated superior efficacy as defined by higher molecular (major molecular response. MMR) and confirmed cytogenetic response rates (CCy. R3) by 1. 2 months, compared to imatinib. The most frequently reported serious adverse reactions in patients with newly diagnosed CP Ph+ CML included pleural effusion (4%), hemorrhage (2%), congestive heart failure (1%), pulmonary hypertension (1%), and pyrexia (1%). Stock indices back vacillating near session lows - - Dow - 2. S& P - 2. 8, Nasdaq Comp - 6. SPY) : Noted in the 1. S& P had stabilized near the June low / April breakout point but needed to initially clear intraday resistance at 1. The late morning rebound hit 1. BMC Software announces expiration of consent solicitation and receipt of requisite consents (BMC) : Co announced that it has received the requisite consents with respect to its previously announced solicitation of Consents with respect to certain proposed amendments to the Supplemental Indenture, dated as of June 4, 2. Company and Wells Fargo Bank, N. A., as trustee to the Base Indenture, dated as of June 4, 2. Company and Wells Fargo Bank, N. A., as trustee governing its 7. Notes due 2. 01. 8 upon the terms and subject to the conditions set forth in the Consent Solicitation Statement and the accompanying Form of Consent, each dated as of June 7, 2. The Solicitation expired at 5: 0. New York City time, on June 1. As of the Expiration Time, the Company received the requisite number of Consents required to approve the Proposed Amendments. These Consents may not be revoked. U. S. Energy reports initial production rate of 8. BOE/D and 3. 0 day average gross production rate of 9. BOE/D from the Beeler #2. H well in south Texas (USEG) : Co announced the successful completion of the Beeler #2. H well at a gross initial production rate of 8. BOE/D. The well had a 3. BOE/D. The Beeler #2. H is the Company's first participated well in Dimmit County, Texas targeting the Buda formation. The Beeler #2. H well was drilled to a total measured depth of 1. The well was completed open hole, without fracture stimulation. The well had an early 2. BOE/D, which consisted of 7. The Company participates in approximately 1. Buda formation and has an approximate 3. Notable movers of interest (: SCANX) : The following are some of today's most notable movers of interest, categorized by market capitalization (large cap over $1. K average daily volume). Large Cap Gainers. NOK (3. 9. 7 +3. 2. WSJ. com reported co and MSFT previously discussed device unit deal. MFC (1. 6. 2. 7 +1. Upgraded to Outperform at BMO Capital Mkts. ALL (4. 7. 4. 1 +0. Announced estimated catastrophe losses for the month of May 2. Large Cap Losers. BLK (2. 53. 9. 7 - 5. Tgt raised to $2. Stifel. KR (3. 3. Beat on EPS by $0. FY1. 4 EPS in- line with consensus. CIG (8. 6. 9 - 4. Upgraded to Buy from Hold at Standpoint Research. Mid Cap Gainers. GME (4. Microsoft (MSFT) will allow Xbox users to play games without an internet connection - reversed used games policy for Xbox One; reiterated as Buy at Stern Agee. GCI (2. 4. 5. 6 +1. Tgt raised to $2. The Benchmark Company; tgt raised to $3. Argus; long- term rating to BUY from HOLD following BLC deal. RHT (4. 6. 9. 5 +1. Beat on EPS by $0. Q2 EPS of $0. 3. 2- 0. Capital IQ consensus Estimate, revs of $3. Capital IQ Consensus Estimate; reaffirmed guidance for FY1. EPS and revs; heard positive comments at Pacific Crest. Mid Cap Losers. KGC (5. Weakness in metals/mining names following gold and silver decline (AEM, AUY, SLW). PHM (1. 9. 0. 7 - 8. Weakness in homebuilders (DHI, LEN). RAD (2. 9 - 6. 8. Reported EPS in- line, revs in- line; lowered GAAP EPS to reflect refinancing transactions, reaffirmed FY1. EBITDA guidance. 1. S& P - 2. 2 edges up slightly off June low and April high/breakout point (SPY) : As noted several times this month in The Technical Take the S& P has probed its 5. Today's breakdown has penetrated these levels to test the June low and April high/bull breakout point at 1. On Track Innovations announces favorable results of Markman hearing in patent infringement suit against T- Mobile (TMUS) (stock halted) (OTIV) : Co announced that it received today the favorable decision on claim construction in the patent infringement lawsuit alleging that Near Field Communication (: NFC) enabled phones sold by T- Mobile USA, Inc. OTI's U. S. Patent No. The Honorable Judge Alison J. Nathan's "adopt[ed] [OTI's] proposed constructions of all four disputed terms." The lawsuit is pending in the United States District Court for the Southern District of New York and was filed in March, 2. Today's decision followed two days of proceedings last month, including a technology tutorial followed by a claim construction argument before the Court. The Court considered the meaning of certain technical terminology used in the '0. Today's decision validates OTI's intellectual property and strongly supports our view that the '0. NFC- enabled phone," said OTI's CEO, Ofer Tziperman. The '0. 43 patent is part of OTI's extensive intellectual property portfolio, including over two dozen issued patents and pending patent applications in the US and numerous more around the world encompassing product applications, software platforms, system and product architecture, product concepts and more in the fields of NFC, contactless payments, secure ID, petroleum and parking solutions. Abbott Labs introduces first FDA- approved hepatitis C gentyping test for patients in the U. S. (ABT) : Co announced that it has introduced the first FDA- approved hepatitis C virus (: HCV) genotyping test for patients in the United States. Abbott's fully automated Real.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
November 2017
Categories |